SNV1521 in Participants with Advanced Solid Tumors

Launched by SYNNOVATION THERAPEUTICS, INC. · Jan 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called SNV1521 for people with advanced solid tumors, which are types of cancer that form in organs and tissues. The main goals of the study are to determine if SNV1521 is safe, how well it is tolerated by patients, and whether it can effectively treat these tumors. Researchers will test various doses to find the best one that works without causing too many side effects.

To participate in this trial, individuals must have advanced or metastatic solid tumors that have not responded to standard treatments or cannot be treated with them due to side effects. Participants should be between 65 and 74 years old, and their overall health should allow them to tolerate the study treatment. They will need to have a life expectancy of at least three months and meet certain health criteria. During the trial, participants will receive the study medication and will be closely monitored for any effects. It’s important to know that some people may not qualify for the trial due to specific health issues, such as recent serious health conditions or other cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Advanced or metastatic solid tumor malignancy
• • Evaluable or Measurable disease (RECIST 1.1 Criteria).
• • ECOG Performance Status 0 or 1.
• • Life expectancy \> 3 months
• Exclusion Criteria:
• • History of other malignancy within the past 2 years
• • Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
• • Significant cardiovascular disease within 6 months
• • Significant gastrointestinal disease
• • HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load
• • Liver dysfunction